We have expanded the capabilities of our NAM technology to create a potential immunotherapy for patients with blood cancers and solid tumors using natural killer, or NK, cells.
NK cells play an important role in the immune system’s fight to kill cancer based on their potent anti-tumor properties. Additionally, NK cells do not require genetic matching, potentially allowing for a universal donor-based therapy when combined with standard-of-care antibodies. However, the applicability of these cells in the clinical setting has been limited due to challenges in developing sufficient numbers of functional cells in culture.
We have developed GDA-201 to address current limitations in NK-based cell therapies by expanding donor NK cells using NAM technology to increase the number and functionality of tumor-targeting NK cells. When combined with targeted antibodies, GDA-201 has shown enhanced antibody-dependent cellular toxicity, or ADCC.1
An investigator-sponsored Phase 1 study evaluating GDA-201 in combination with antibodies in adult patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma is ongoing. Data from this study provides the basis for initiating a multi-center, Phase 1/2 study in patients with non-Hodgkin lymphoma, which is expected to begin next year. Learn more about the Phase 1 study (NCT03019666) at www.clinicaltrials.gov.
1 First-in-Human Phase I Study of Nicotinamide-Expanded Related Donor Natural Killer Cells for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma. Bachanova V. Presented at the 2019 TCT Meetings of ASBMT and CIBMTR.